Microsize antibodies for $99 | Learn More >>

Mouse Sertoli Cell Development

Also showing Mouse Sertoli Cell Differentiation

$305
50 tests
100 µl
This Cell Signaling Technology antibody is conjugated to Alexa Fluor® 647 fluorescent dye and tested in-house for direct flow cytometry and immunofluorescent analysis in human cells. The antibody is expected to exhibit the same species cross-reactivity as the unconjugated Sox9 (D8G9H) Rabbit mAb #82630.
APPLICATIONS
REACTIVITY
Human, Mouse

Application Methods: Flow Cytometry, Immunofluorescence (Immunocytochemistry)

Background: Sox9 is a transcription factor with an HMG-box DNA binding domain that has homology to the HMG domain of the mammalian testis-determining factor, SRY (1). Sox9 regulates several important processes during embryonic development including chondrogenesis, during which it contributes to skeletal formation and digit specification (2,3). Sox9 also coordinates with steroidogenic factor-1 to direct Sertoli cell-specific expression of anti-Mullerian hormone during embryogenesis, thereby contributing to male sex determination (4). In addition, Sox9 is reportedly involved in the maintenance of adult stem cell populations, including multipotent neural stem cells (5), hair follicle stem cells (6), and mammary stem cells (7). Recent interest has focused on the role of Sox9 in tumor biology. For example, research studies have shown that Sox9 expression in lung adenocarcinoma induces a mesenchymal phenotype in tumor cells (8). Other research studies have shown that YAP1 induced upregulation of Sox9 confers cancer stem cell like properties on esophageal cancer cells (9). Moreover, Sox9 expression has been linked with several other tumor types including ovarian, prostate, and pancreatic malignancies (10-12).

$115
20 µl
$269
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse

Application Methods: Flow Cytometry, Immunofluorescence (Immunocytochemistry), Immunohistochemistry (Paraffin), Western Blotting

Background: Sox9 is a transcription factor with an HMG-box DNA binding domain that has homology to the HMG domain of the mammalian testis-determining factor, SRY (1). Sox9 regulates several important processes during embryonic development including chondrogenesis, during which it contributes to skeletal formation and digit specification (2,3). Sox9 also coordinates with steroidogenic factor-1 to direct Sertoli cell-specific expression of anti-Mullerian hormone during embryogenesis, thereby contributing to male sex determination (4). In addition, Sox9 is reportedly involved in the maintenance of adult stem cell populations, including multipotent neural stem cells (5), hair follicle stem cells (6), and mammary stem cells (7). Recent interest has focused on the role of Sox9 in tumor biology. For example, research studies have shown that Sox9 expression in lung adenocarcinoma induces a mesenchymal phenotype in tumor cells (8). Other research studies have shown that YAP1 induced upregulation of Sox9 confers cancer stem cell like properties on esophageal cancer cells (9). Moreover, Sox9 expression has been linked with several other tumor types including ovarian, prostate, and pancreatic malignancies (10-12).

$305
50 tests
100 µl
This Cell Signaling Technology antibody is conjugated to phycoerythrin (PE) and tested in-house for direct flow cytometry analysis in human cells. This antibody is expected to exhibit the same species cross-reactivity as the unconjugated Sox9 (D8G9H) Rabbit mAb #82630.
APPLICATIONS
REACTIVITY
Human, Mouse

Application Methods: Flow Cytometry

Background: Sox9 is a transcription factor with an HMG-box DNA binding domain that has homology to the HMG domain of the mammalian testis-determining factor, SRY (1). Sox9 regulates several important processes during embryonic development including chondrogenesis, during which it contributes to skeletal formation and digit specification (2,3). Sox9 also coordinates with steroidogenic factor-1 to direct Sertoli cell-specific expression of anti-Mullerian hormone during embryogenesis, thereby contributing to male sex determination (4). In addition, Sox9 is reportedly involved in the maintenance of adult stem cell populations, including multipotent neural stem cells (5), hair follicle stem cells (6), and mammary stem cells (7). Recent interest has focused on the role of Sox9 in tumor biology. For example, research studies have shown that Sox9 expression in lung adenocarcinoma induces a mesenchymal phenotype in tumor cells (8). Other research studies have shown that YAP1 induced upregulation of Sox9 confers cancer stem cell like properties on esophageal cancer cells (9). Moreover, Sox9 expression has been linked with several other tumor types including ovarian, prostate, and pancreatic malignancies (10-12).

$305
50 tests
100 µl
This Cell Signaling Technology antibody is conjugated to Alexa Fluor® 488 fluorescent dye and tested in-house for direct flow cytometry and immunofluorescent analysis in human cells. The antibody is expected to exhibit the same species cross-reactivity as the unconjugated Sox9 (D8G8H) Rabbit mAb #82630.
APPLICATIONS
REACTIVITY
Human, Mouse

Application Methods: Flow Cytometry, Immunofluorescence (Immunocytochemistry)

Background: Sox9 is a transcription factor with an HMG-box DNA binding domain that has homology to the HMG domain of the mammalian testis-determining factor, SRY (1). Sox9 regulates several important processes during embryonic development including chondrogenesis, during which it contributes to skeletal formation and digit specification (2,3). Sox9 also coordinates with steroidogenic factor-1 to direct Sertoli cell-specific expression of anti-Mullerian hormone during embryogenesis, thereby contributing to male sex determination (4). In addition, Sox9 is reportedly involved in the maintenance of adult stem cell populations, including multipotent neural stem cells (5), hair follicle stem cells (6), and mammary stem cells (7). Recent interest has focused on the role of Sox9 in tumor biology. For example, research studies have shown that Sox9 expression in lung adenocarcinoma induces a mesenchymal phenotype in tumor cells (8). Other research studies have shown that YAP1 induced upregulation of Sox9 confers cancer stem cell like properties on esophageal cancer cells (9). Moreover, Sox9 expression has been linked with several other tumor types including ovarian, prostate, and pancreatic malignancies (10-12).

$305
100 µl
This Cell Signaling Technology antibody is conjugated to biotin under optimal conditions. The biotinylated antibody is expected to exhibit the same species cross-reactivity as the unconjugated Sox9 (D8G9H) Rabbit mAb #82630.
APPLICATIONS
REACTIVITY
Human, Mouse

Application Methods: Western Blotting

Background: Sox9 is a transcription factor with an HMG-box DNA binding domain that has homology to the HMG domain of the mammalian testis-determining factor, SRY (1). Sox9 regulates several important processes during embryonic development including chondrogenesis, during which it contributes to skeletal formation and digit specification (2,3). Sox9 also coordinates with steroidogenic factor-1 to direct Sertoli cell-specific expression of anti-Mullerian hormone during embryogenesis, thereby contributing to male sex determination (4). In addition, Sox9 is reportedly involved in the maintenance of adult stem cell populations, including multipotent neural stem cells (5), hair follicle stem cells (6), and mammary stem cells (7). Recent interest has focused on the role of Sox9 in tumor biology. For example, research studies have shown that Sox9 expression in lung adenocarcinoma induces a mesenchymal phenotype in tumor cells (8). Other research studies have shown that YAP1 induced upregulation of Sox9 confers cancer stem cell like properties on esophageal cancer cells (9). Moreover, Sox9 expression has been linked with several other tumor types including ovarian, prostate, and pancreatic malignancies (10-12).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Western Blotting

Background: The family of Trk receptor tyrosine kinases consists of TrkA, TrkB, and TrkC. While the sequence of these family members is highly conserved, they are activated by different neurotrophins: TrkA by NGF, TrkB by BDNF or NT4, and TrkC by NT3 (1). Neurotrophin signaling through these receptors regulates a number of physiological processes, such as cell survival, proliferation, neural development, and axon and dendrite growth and patterning (1). In the adult nervous system, the Trk receptors regulate synaptic strength and plasticity. TrkA regulates proliferation and is important for development and maturation of the nervous system (2). Phosphorylation at Tyr490 is required for Shc association and activation of the Ras-MAP kinase cascade (3,4). Residues Tyr674/675 lie within the catalytic domain, and phosphorylation at these sites reflects TrkA kinase activity (3-6). Point mutations, deletions, and chromosomal rearrangements (chimeras) cause ligand-independent receptor dimerization and activation of TrkA (7-10). TrkA is activated in many malignancies including breast, ovarian, prostate, and thyroid carcinomas (8-13). Research studies suggest that expression of TrkA in neuroblastomas may be a good prognostic marker as TrkA signals growth arrest and differentiation of cells originating from the neural crest (10).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: The family of Trk receptor tyrosine kinases consists of TrkA, TrkB, and TrkC. While the sequence of these family members is highly conserved, they are activated by different neurotrophins: TrkA by NGF, TrkB by BDNF or NT4, and TrkC by NT3 (1). Neurotrophin signaling through these receptors regulates a number of physiological processes, such as cell survival, proliferation, neural development, and axon and dendrite growth and patterning (1). In the adult nervous system, the Trk receptors regulate synaptic strength and plasticity. TrkA regulates proliferation and is important for development and maturation of the nervous system (2). Phosphorylation at Tyr490 is required for Shc association and activation of the Ras-MAP kinase cascade (3,4). Residues Tyr674/675 lie within the catalytic domain, and phosphorylation at these sites reflects TrkA kinase activity (3-6). Point mutations, deletions, and chromosomal rearrangements (chimeras) cause ligand-independent receptor dimerization and activation of TrkA (7-10). TrkA is activated in many malignancies including breast, ovarian, prostate, and thyroid carcinomas (8-13). Research studies suggest that expression of TrkA in neuroblastomas may be a good prognostic marker as TrkA signals growth arrest and differentiation of cells originating from the neural crest (10).

$305
100 µl
This Cell Signaling Technology antibody is conjugated to biotin under optimal conditions. The biotinylated antibody is expected to exhibit the same species cross-reactivity as the unconjugated Trk (pan) (A7H6R) Rabbit mAb #92991.
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Western Blotting

Background: The family of Trk receptor tyrosine kinases consists of TrkA, TrkB, and TrkC. While the sequence of these family members is highly conserved, they are activated by different neurotrophins: TrkA by NGF, TrkB by BDNF or NT4, and TrkC by NT3 (1). Neurotrophin signaling through these receptors regulates a number of physiological processes, such as cell survival, proliferation, neural development, and axon and dendrite growth and patterning (1). In the adult nervous system, the Trk receptors regulate synaptic strength and plasticity. TrkA regulates proliferation and is important for development and maturation of the nervous system (2). Phosphorylation at Tyr490 is required for Shc association and activation of the Ras-MAP kinase cascade (3,4). Residues Tyr674/675 lie within the catalytic domain, and phosphorylation at these sites reflects TrkA kinase activity (3-6). Point mutations, deletions, and chromosomal rearrangements (chimeras) cause ligand-independent receptor dimerization and activation of TrkA (7-10). TrkA is activated in many malignancies including breast, ovarian, prostate, and thyroid carcinomas (8-13). Research studies suggest that expression of TrkA in neuroblastomas may be a good prognostic marker as TrkA signals growth arrest and differentiation of cells originating from the neural crest (10).

$111
20 µl
$260
100 µl
APPLICATIONS
REACTIVITY
Mouse, Rat

Application Methods: Western Blotting

Background: Retinoids (vitamin A and its active retinoic acid derivatives) are non-steroid hormones that regulate cell proliferation, differentiation and apoptosis. Retinoic acid receptors (RARalpha, -beta and -gamma) and retinoid X receptors (RXRalpha, -beta and -gamma) are nuclear receptors that function as RAR-RXR heterodimers or RXR homodimers (1-2). In response to retinoid binding, these dimers control gene expression by binding to specific retinoic acid response elements, by recruiting cofactors and the transcriptional machinery, and by indirectly regulating chromatin structure. Finally, ligand binding and phosphorylation of RARalpha by JNK at Thr181, Ser445 and Ser461 controls the stability of RAR-RXR through the ubiquitin-proteasome pathway (3-4). At least four distinct genetic lesions affect RARalpha and result in acute promyelocytic leukemia (APL). The t(15;17) translocation that results in the PML-RARalpha fusion protein is responsible for more than 99% of APL cases, and the fusion protein inhibits PML-dependent apoptotic pathways in a dominant negative fashion. In addition PML-RARalpha inhibits transcription of retinoic acid target genes by recruiting co-repressors, attenuating myeloid differentiation (5-6).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse

Application Methods: Chromatin IP, Immunoprecipitation, Western Blotting

Background: Retinoids (vitamin A and its active retinoic acid derivatives) are non-steroid hormones that regulate cell proliferation, differentiation and apoptosis. Retinoic acid receptors (RARalpha, -beta and -gamma) and retinoid X receptors (RXRalpha, -beta and -gamma) are nuclear receptors that function as RAR-RXR heterodimers or RXR homodimers (1-2). In response to retinoid binding, these dimers control gene expression by binding to specific retinoic acid response elements, by recruiting cofactors and the transcriptional machinery, and by indirectly regulating chromatin structure. Finally, ligand binding and phosphorylation of RARalpha by JNK at Thr181, Ser445 and Ser461 controls the stability of RAR-RXR through the ubiquitin-proteasome pathway (3-4). At least four distinct genetic lesions affect RARalpha and result in acute promyelocytic leukemia (APL). The t(15;17) translocation that results in the PML-RARalpha fusion protein is responsible for more than 99% of APL cases, and the fusion protein inhibits PML-dependent apoptotic pathways in a dominant negative fashion. In addition PML-RARalpha inhibits transcription of retinoic acid target genes by recruiting co-repressors, attenuating myeloid differentiation (5-6).

$111
20 µl
$260
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: Bax is a key component for cellular induced apoptosis through mitochondrial stress (1). Upon apoptotic stimulation, Bax forms oligomers and translocates from the cytosol to the mitochondrial membrane (2). Through interactions with pore proteins on the mitochondrial membrane, Bax increases the membrane's permeability, which leads to the release of cytochrome c from mitochondria, activation of caspase-9 and initiation of the caspase activation pathway for apoptosis (3,4).

$260
100 µl
APPLICATIONS
REACTIVITY
Mouse, Rat

Application Methods: Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blotting

Background: Bax is a key component for cellular induced apoptosis through mitochondrial stress (1). Upon apoptotic stimulation, Bax forms oligomers and translocates from the cytosol to the mitochondrial membrane (2). Through interactions with pore proteins on the mitochondrial membrane, Bax increases the membrane's permeability, which leads to the release of cytochrome c from mitochondria, activation of caspase-9 and initiation of the caspase activation pathway for apoptosis (3,4).